# Everolimus Modulation of Anti-tumor T CD4 Immune Responses

> **NCT02837757** · NA · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Renal Cancer

## Interventions

- **OTHER:** Biological samples

## Key facts

- **NCT ID:** NCT02837757
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2019-12-18
- **Final completion:** 2019-12-18
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** difficulty of patient recruitment
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837757, "Everolimus Modulation of Anti-tumor T CD4 Immune Responses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02837757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*